Refine
Has Fulltext
- yes (19)
Is part of the Bibliography
- yes (19)
Year of publication
Document Type
- Journal article (19)
Language
- English (19)
Keywords
- CXCR4 (8)
- PET (7)
- theranostics (6)
- PRRT (4)
- chemokine receptor (3)
- molecular imaging (3)
- multiple myeloma (3)
- DOTATOC (2)
- NET (2)
- PET/CT (2)
- SSTR (2)
- fibroblast activation protein (2)
- medicine (2)
- radionuclide therapy (2)
- sarcoidosis (2)
- somatostatin receptor (2)
- 11C-Methionine PET/CT (1)
- 18F-FDG PET/CT (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- Arginine (1)
- C-X-C motif chemokine receptor 4 (1)
- CXCR4/SDF-1 (1)
- DOTA-EB-TATE (1)
- FDG (1)
- FDG PET/CT (1)
- Hyperkalaemia (1)
- Lysine (1)
- MAG3 (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Pentixafor (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Somatostatin receptor expression (1)
- [177Lu]/[90Y]PentixaTher (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- agreement (1)
- amino acids (1)
- androgen deprivation therapy (1)
- autologous transplantation (1)
- biokinetics (1)
- biomarker (1)
- bone disease (1)
- cancer (1)
- cells (1)
- comparability (1)
- detection rate (1)
- endoradiotherapy (1)
- evans blue (1)
- head and neck cancer (1)
- hyperkalemia (1)
- in vivo imaging (1)
- intraindividual comparison (1)
- involvement (1)
- kidney function (1)
- malignancies (1)
- metabolic tumour volume (MTV) (1)
- microenvironment (1)
- neuroendocrine tumor (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (1)
- pleural mesothelioma (1)
- positron emission tomography (1)
- prostate-specific membrane antigen (PSMA) (1)
- radioligand therapy (1)
- recurrent prostate cancer (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin receptors (1)
- survival (1)
- total lesion PSMA (1)
- vestibular schwannoma (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (19)
- Medizinische Klinik und Poliklinik II (6)
- Pathologisches Institut (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Medizinische Klinik und Poliklinik I (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Urologische Klinik und Poliklinik (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
EU-Project number / Contract (GA) number
- 701983 (1)
Background
Peptide receptor radionuclide therapy (PRRT) is applied in patients with advanced neuroendocrine tumors. Co-infused amino acids (AA) should prevent nephrotoxicity. The aims of this study were to correlate the incidence of AA-induced hyperkalemia (HK) (≥5.0 mmol/l) and to identify predictors of AA-induced severe HK (>6.0).
Methods
In 38 patients, standard activity of \(^{177}Lu\)-labelled somatostatin analogs was administered. Pre-therapeutic kidney function was assessed by renal scintigraphy and laboratory tests. For kidney protection, AA was co-infused. Biochemical parameters (potassium, glomerular filtration rate, creatinine, blood urea nitrogen (BUN), sodium, phosphate, chloride, and lactate dehydrogenase (LDH)) were obtained prior to 4 and 24 h after the AA infusion. Incidence of HK (≥5.0) was correlated with pre-therapeutic kidney function and serum parameters. Formulas for the prediction of severe hyperkalemia (>6.0) were computed and prospectively validated.
Results
At 4 h, HK (≥5.0) was present in 94.7% with severe HK (>6.0) in 36.1%. Values normalized after 24 h in 84.2%. Pre-therapeutic kidney function did not correlate with the incidence of severe HK.
Increases in K+ were significantly correlated with decreases in phosphate (r = −0.444, p < 0.005) and increases in BUN (r = 0.313, p = 0.056). A baseline BUN of >28 mg/dl had a sensitivity of 84.6% and a specificity of 60.0% (AUC = 0.75) in predicting severe HK of >6.0 (phosphate, AUC = 0.37).
Computing of five standard serum parameters (potassium, BUN, sodium, phosphate, LDH) resulted in a sensitivity of 88.9% and a specificity of 79.3% for the prediction of severe HK >6.0 (accuracy = 81.6%).
Conclusions
A combination of serum parameters predicted prospectively the occurrence of relevant HK with an accuracy of 81.6% underlining its potential utility for identifying ‘high-risk’ patients prone to PRRT.